💡 Aurobindo Pharma received USFDA approval for a new drug with an estimated market size of $50.2 million.
What Happened
Aurobindo Pharma Limited has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Glycerol Phenylbutyrate Oral Liquid, 1.1 grams per mL. The product is bioequivalent and therapeutically equivalent to the reference listed drug Ravicti Oral Liquid. The company announced the product will be manufactured at Unit-III and launched immediately.
Key Details
- Company: Aurobindo Pharma Limited
- Event Type: Regulatory
- Filing Date: 17-Apr-2026 10:40:21
- NSE Filing: View Document
Why It Matters
This USFDA approval represents a significant regulatory milestone for Aurobindo Pharma, granting the company access to a new market segment. The approved drug, indicated for chronic management of urea cycle disorders, has an estimated market size of US$ 50.2 million according to IQVIA data for the twelve months ending February 2026. This approval adds to Aurobindo's growing portfolio of ANDA approvals, which now totals 579 (556 final and 23 tentative approvals) from the USFDA. The immediate launch plans suggest the company is positioned to quickly capitalize on this regulatory clearance, potentially contributing to future revenue streams from the US market.
Disclaimer: This is publicly available information sourced from NSE. Not investment advice.
Get signals like this instantly
Free Telegram alerts within 2 minutes of NSE filing
Join SuperStock Free